BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
77.28
-1.82 (-2.30%)
At close: Jan 30, 2026, 4:00 PM EST
77.27
-0.01 (-0.01%)
After-hours: Jan 30, 2026, 4:18 PM EST
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 21 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $78.81, which forecasts a 1.98% increase in the stock price over the next year. The lowest target is $49 and the highest is $110.
Price Target: $78.81 (+1.98%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 9 | 9 | 9 | 8 |
| Buy | 9 | 9 | 9 | 10 | 12 | 13 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 18 | 19 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $80 | Buy | Initiates | $80 | +3.52% | Jan 28, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $84 → $88 | Buy | Maintains | $84 → $88 | +13.87% | Jan 20, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $80 → $86 | Strong Buy | Maintains | $80 → $86 | +11.28% | Jan 8, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $96 | Buy | Initiates | $96 | +24.22% | Jan 6, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $75 → $86 | Buy | Maintains | $75 → $86 | +11.28% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
508.46M
from 221.90M
Increased by 129.14%
Revenue Next Year
909.94M
from 508.46M
Increased by 78.96%
EPS This Year
-3.55
from -2.88
EPS Next Year
-1.90
from -3.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 593.7M | 1.3B | ||||
| Avg | 508.5M | 909.9M | ||||
| Low | 447.3M | 568.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 167.5% | 155.9% | ||||
| Avg | 129.1% | 79.0% | ||||
| Low | 101.6% | 11.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.19 | -0.71 | ||||
| Avg | -3.55 | -1.90 | ||||
| Low | -3.59 | -2.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.